HPV vaccine introduction in the Americas: a decade of progress and lessons learned

References

• World Health Orgranization. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;92(19):241–268.
   PubMedGoogle Scholar
• Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30:F55–70.
   PubMed Web of Science ®Google Scholar
• Reid R, Stanhope CR, Herschman BR, et al. Genital warts and cervical cancer. Cancer. 1982;50:337–387.
   PubMedGoogle Scholar
• Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–265.
   PubMed Web of Science ®Google Scholar
• de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Heal. 2020;8:e180–90.
   PubMed Web of Science ®Google Scholar
• de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141:664–670.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer Today. GLOBOCAN 2020 2020. cited 2021 Sept 8 https://gco.iarc.fr/today.
   Google Scholar
• Pan American Health Organization. Regional Strategy and Plan of Action for Cervical. Cancer prevention and control in Latin America and the Caribbean. Washington (D.C); 2008.
   Google Scholar
• Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383:1340–1348.
   PubMed Web of Science ®Google Scholar
• Pan American Health Organization. Plan of action for cervical cancer prevention and control 2018-2030. Washington (D.C); 2018.
   Google Scholar
• World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem and its associated goals and targets for the period 2020 – 2030. Geneva; 2020.
   Google Scholar
• Luciani S, Bruni L, Agurto I, et al. HPV vaccine implementation and monitoring in Latin America. Salud Publica Mex. 2018;60:683–692.
   PubMed Web of Science ®Google Scholar
• Wendland EM, Kops NL, Bessel M, et al. Effectiveness of a universal vaccination program with an HPV quadrivalent vaccine in young Brazilian women. Vaccine. 2021;39:1840–1845.
   PubMed Web of Science ®Google Scholar
• González JV, Deluca GD, Correa RM, et al. Strong reduction in prevalence of HPV16/18 and closely related HPV types in sexually active adolescent women following the introduction of HPV vaccination in Argentina. Papillomavirus Res. 2020;10:100208.
   PubMed Web of Science ®Google Scholar
• Bruni L, Saura-Lázaro A, Montoliu A, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med. 2021;144:106399.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cecolin product overview. . 2021 Accessed 19 09 2022 https://portal-uat.who.int/pqweb/content/cecolin%C2%AE.
   Google Scholar
• Patel H, Wagner M, Singhal P, et al. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013;13. DOI:10.1186/1471-2334-13-39
   PubMed Web of Science ®Google Scholar
• Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199:805–814.
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Quint WGV, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–1056.
   PubMed Web of Science ®Google Scholar
• Serrano B, De Sanjosé S, Tous S, et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015;(51):1732–1741. DOI:10.1016/j.ejca.2015.06.001
   PubMedGoogle Scholar
• Food and Drug Administration (FDA). Gardasil 9 Product Information 2020. https://www.fda.gov/vaccines-blood-biologics/vaccines/gardasil-9 (cited 2021 Oct 8).
   Google Scholar
• World Health Organization. Global advisory committee on vaccine Safety, 4-5 December 2019. Wkly Epidemiol Rec. 2020;95:25–36.
   Google Scholar
• Donahue JG, Kieke BA, Lewis EM, et al. Near real-time surveillance to assess the safety of the 9-valent human papillomavirus vaccine. Pediatrics. 2019;144. DOI:10.1542/peds.2019-1808.
   PubMed Web of Science ®Google Scholar
• Lopez MS, Baker ES, Maza M, et al. Cervical cancer prevention and treatment in Latin America. J Surg Oncol. 2017;115:615–618.
   PubMed Web of Science ®Google Scholar
• Harper DM, DeMars LR. HPV vaccines – a review of the first decade. Gynecol Oncol. 2017;146:196–204.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer. 2007;97:1322–1328.
   PubMed Web of Science ®Google Scholar
• Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29:8443–8450.
   PubMed Web of Science ®Google Scholar
• Pan American Health Organization. Report on the 25th meeting of the PAHO technical adviosry group (TAG) on vaccine-preventable diseases - July 2019. 2019.
   Google Scholar
• World Health Orgranization. Meeting of the strategic advisory group of experts on immunization, April 2022: conclusions and recommendations Wkly Epidemiol Rec. 2022;97:261–276.
   Google Scholar
• Andrus JK, Jauregui B, de Oliveira LH, et al. Challenges to building capacity for evidence-based new vaccine policy in developing countries. Health Aff. 2011;30:1104–1112.
   PubMed Web of Science ®Google Scholar
• Jauregui B, Janusz CB, Clark AD, et al. ProVac global initiative: a vision shaped by ten years of supporting evidence-based policy decisions. Vaccine. 2015;33:A21–7.
   PubMed Web of Science ®Google Scholar
• Janusz CB, Jauregui B, Sinha A, et al. Performing country-led economic evaluations to inform immunization policy: proVac experiences in Latin America and the Caribbean. Value Heal Reg Issues. 2012;1:248–253.
   PubMedGoogle Scholar
• PAHO. PAHO/WHO-UNICEF joint reporting form country reports n.d. https://www3.paho.org/hq/index.php?option=com_content&view=article&id=2043:data-statistics-immunization&Itemid=2032&lang=en (cited 2021 Oct 8).
   Google Scholar
• Pan American Health Organization. Methodology to Calculate HPV vaccine coverage in the region of the Americas. Washington (D.C); 2019.
   Google Scholar
• Toh ZQ, Russell FM, Garland SM, et al. Human papillomavirus vaccination after COVID-19. JNCI Cancer Spectr. 2021;5:1–7.
   Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JML, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14:958–966.
   PubMed Web of Science ®Google Scholar
• García-Perdomo HA, Osorio JC, Fernandez A, et al. The effectiveness of vaccination to prevent the papillomavirus infection: a systematic review and meta-analysis. Epidemiol Infect. 2019;147. DOI:10.1017/S0950268818003679
   Web of Science ®Google Scholar
• Pan American Health Organization. HPV vaccination in the Americas: lessons learned from the introduction and communication strategies. Meeting Report, 24-26 October 2017. 2017.
   Google Scholar
• Pan American Health Organization. HPV vaccination: towards the elimination of cervical cancer in the Caribbean countries. Virtual Meeting Report, 22-23 and 29-30 October 2020. 2020.
   Google Scholar
• Pan American Health Organization. 21st meeting of the technical advisory group on vaccine-preventable diseases for the Americas. Meeting Report, 3-5 July 2013, Quito. 2013.
   Google Scholar
• du Québec G. History and Aims of the HPV vaccination program in Quebec n.d. https://www.quebec.ca/en/health/advice-and-prevention/vaccination/human-papillomavirus-hpv-vaccination-program/ (cited 2022 Jul 7).
   Google Scholar
• Basu P, Malvi SG, Joshi S, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 2021;22:1518–1529.
   PubMed Web of Science ®Google Scholar
• Kuter BJ, Garland SM, Giuliano AR, et al. Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: what’s ongoing, what’s needed? Prev Med. 2021;144:106321.
   PubMed Web of Science ®Google Scholar
• Fregnani JHTG, Carvalho AL, Eluf-Neto J, et al. A school-based human papillomavirus vaccination program in barretos, Brazil: final results of a demonstrative study. PLoS One. 2013;8:1–9.
   Web of Science ®Google Scholar
• Faisal-Cury A, Levy RB, Tourinho MF, et al. Vaccination coverage rates and predictors of HPV vaccination among eligible and non-eligible female adolescents at the Brazilian HPV vaccination public program. BMC Public Health. 2020;20:1–12.
   PubMed Web of Science ®Google Scholar
• Arams R, Weinstock RE, Satterthwaite Muresianu E, et al. In the name of prevention: maternal perspectives on school-based HPV vaccination in rural Southern Chile. Adolesc Health Med Ther. 2021;12:27–36.
   PubMed Web of Science ®Google Scholar
• Liebermann E, Devanter N, Van FG, et al. Parent-level barriers and facilitators to HPV vaccine implementation in Santo Domingo, Dominican Republic. J Community Health. 2020;45:1061–1066.
   PubMed Web of Science ®Google Scholar
• Gomes JM, Silva BM, de Sousa Santos EF, et al. Human Papillomavirus (HPV) and the quadrivalent HPV vaccine among Brazilian adolescents and parents: factors associated with and divergences in knowledge and acceptance. PLoS One. 2020;15:1–13.
   Web of Science ®Google Scholar
• Daniels V, Saxena K, Roberts C, et al. Impact of reduced HPV coverage rates due to COVID-19 in the US: a model based analysis. Vaccine. 2021;39:2731–2735.
   PubMed Web of Science ®Google Scholar
• Simas C, Munoz N, Arregoces L, et al. HPV vaccine confidence and cases of mass psychogenic illness following immunization in Carmen de Bolivar, Colombia. Hum Vaccines Immunother. 2019;15:163–166.
   PubMed Web of Science ®Google Scholar
• Pan American Health Organization. PAHO Revolving Fund 2021. https://www.paho.org/en/revolvingfund (cited 2021 Nov 11).
   Google Scholar
• Unicef Supply Division. Human papillomavirus vaccine: supply and demand update. ; 2020. [2022 Sept 19]. Available from: https://www.unicef.org/supply/media/5406/file/Human-Papillomavirus-Vaccine-Market-Update-October2020.pdf
   Google Scholar